[Skip to Content]
[Skip to Content Landing]

July 2019 - April 2015

Decade

Year

Issue

February 2018, Vol 4, No. 2, Pages 143-266

Original Investigation

Critical Lessons From High-Value Oncology Practices

Abstract Full Text
free access has audio
JAMA Oncol. 2018;4(2):164-171. doi:10.1001/jamaoncol.2017.3803

This qualitative analysis of interview results assesses the attributes of “positive deviant” oncology practices that deliver high-quality cancer care at low total cost for testing and adoption by other practices.

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):173-182. doi:10.1001/jamaoncol.2017.3064

This systematic review and meta-analysis compares the incidence and risk of endocrine adverse events following treatment with US Food and Drug Administration-approved immune checkpoint inhibitor regimens.

Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival

Abstract Full Text
free access has audio
JAMA Oncol. 2018;4(2):183-189. doi:10.1001/jamaoncol.2017.3326

This cohort study assesses the association of locoregional surgery at diagnosis for small intestine neuroendocrine tumors with survival among Swedish patients.

Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):190-195. doi:10.1001/jamaoncol.2017.4211

Using a Markov simulation model based on the United Kingdom Collaborative Trial of Ovarian Cancer Screening clinical trial, this study examines the cost-effectiveness of multimodal screening for ovarian cancer in the United States and the association of screening with mortality.

Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):196-202. doi:10.1001/jamaoncol.2017.4218

This phase 2 randomized clinical trial evaluates the effects of pazopanib in combination with paclitaxel vs paclitaxel and placebo on survival in patients with recurrent ovarian cancer.

Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):203-209. doi:10.1001/jamaoncol.2017.4298

This validation study compares the American Joint Committee on Cancer eighth edition prognostic stage with the anatomic stage among patients with breast cancer in a single-institution cohort and a large population database.

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):210-216. doi:10.1001/jamaoncol.2017.4427

This systematic review and meta-analysis of 5 randomized clinical trials determines the efficacy of checkpoint inhibitors compared with docetaxel as a second-line therapy for advanced non–small cell lung carcinoma.

Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):217-224. doi:10.1001/jamaoncol.2017.3588

This cohort study evaluates the use of positron emission tomography to identify patient phenotypes for androgen receptor expression and glycolysis in patients with metastatic castration-resistant prostate cancer.

Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(2):e173580. doi:10.1001/jamaoncol.2017.3580

This study evaluates the frequency of mismatch repair deficiency testing in adults with colorectal cancer.

Brief Report

Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):225-229. doi:10.1001/jamaoncol.2017.2374

This cohort study assesses the comparative effectiveness of adjuvant chemotherapy vs observation for patients with pT3/T4 and/or pN+ urothelial carcinoma of the bladder pretreated with neoadjuvant chemotherapy and radial cystectomy.

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):230-234. doi:10.1001/jamaoncol.2017.2380

This single-arm, phase 2 study of adults with relapsed or refractory B-cell acute lymphoblastic leukemia evaluates the efficacy and safety of treatment with inotuzumab ozogamicin plus low-intensity chemotherapy.

Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):235-238. doi:10.1001/jamaoncol.2017.2918

This study investigates anaplastic lymphoma kinase rearrangements in a large series of peritoneal mesothelioma tumors.

Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(2):e172908. doi:10.1001/jamaoncol.2017.2908

This study compares rates of disease progression and overall survival of patients with melanoma treated with propranolol with patients not treated with propranolol.

Research Letter

Challenges, Perceptions, and Readiness of Oncology Clinicians for the MACRA Quality Payment Program

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):252-253. doi:10.1001/jamaoncol.2017.3773

This study surveys oncologists, hematologists, and practice administrators to gain an understanding of their perceptions of and readiness to participate in the MACRA Quality Payment Program.

Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):253-255. doi:10.1001/jamaoncol.2017.3808

This cohort study evaluates the clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy.

Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):255-257. doi:10.1001/jamaoncol.2017.4473

This study examines the nonresearch payments received by committee and board members of oncology clinical pathway vendors.

Primary Cancer vs Competing Causes of Death in Survivors of Head and Neck Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):257-259. doi:10.1001/jamaoncol.2017.4478

This cohort study determines the probability and estimates the time point after diagnosis when death from competing causes becomes more common than that from primary head and neck cancer.

Restaging Abdominopelvic Computed Tomography Before Surgery After Preoperative Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):259-262. doi:10.1001/jamaoncol.2017.4596

This study examines the association of diagnostic yield and postsurgical recurrence-free survival with restaging abdominopelvic computed tomography performed before surgery after receiving chemoradiotherapy in patients with locally advanced rectal cancer.

Review

Biosimilars in Oncology in the United States: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(2):241-247. doi:10.1001/jamaoncol.2017.2004

This review discusses the development, opportunities, and potential problems of biosimilar cancer drugs.

JAMA Network Insights

Management of the Node-Positive Axilla in Breast Cancer in 2017: Selecting the Right Option

Abstract Full Text
JAMA Oncol. 2018;4(2):250-251. doi:10.1001/jamaoncol.2017.3625

This JAMA Network Insights article explores the management of the node-positive axilla in breast cancer in 2017.

JAMA Oncology Clinical Challenge

Hypermetabolic Vocal Cord Focus With Recurrent Oral Cancer History

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(2):248-249. doi:10.1001/jamaoncol.2017.3180

A woman in her 80s with a history of recurrent oral cancer was diagnosed with squamous cell carcinoma located at the margin of a palatal graft; surveillance imaging reveals metabolic activity in her left vocal cord. What is your diagnosis?

Viewpoint

A Policy That Encourages Wastage of Expensive Medications—The JW Modifier

Abstract Full Text
JAMA Oncol. 2018;4(2):155-156. doi:10.1001/jamaoncol.2017.3997

This Viewpoint explores the legislation that allows payment for wastage of injectable medications.

Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers

Abstract Full Text
JAMA Oncol. 2018;4(2):157-158. doi:10.1001/jamaoncol.2017.4182

This Viewpoint examines the recent US Food and Drug Administration approval of pembrolizumab and its implications for precision oncology and tumor-type classifications.

Invited Commentary

Strategies to Achieve High-Value Oncology Care—A Beginning

Abstract Full Text
JAMA Oncol. 2018;4(2):171-172. doi:10.1001/jamaoncol.2017.3794

Status of Testing for High-Level Microsatellite Instability/Deficient Mismatch Repair in Colorectal Carcinoma

Abstract Full Text
online only
JAMA Oncol. 2018;4(2):e173574. doi:10.1001/jamaoncol.2017.3574
Cancer Care Chronicles

Where Is the Road Map for Glioblastoma?

Abstract Full Text
JAMA Oncol. 2018;4(2):159. doi:10.1001/jamaoncol.2017.3073
Poetry and Oncology

The Waiting Room

Abstract Full Text
JAMA Oncol. 2018;4(2):266. doi:10.1001/jamaoncol.2017.2703
Comment & Response

Delayed Adjuvant Chemotherapy and Survival After Lung Cancer Surgery

Abstract Full Text
JAMA Oncol. 2018;4(2):262. doi:10.1001/jamaoncol.2017.0167

Delayed Adjuvant Chemotherapy and Survival After Lung Cancer Surgery—Reply

Abstract Full Text
JAMA Oncol. 2018;4(2):262-263. doi:10.1001/jamaoncol.2017.2760

Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer

Abstract Full Text
JAMA Oncol. 2018;4(2):263. doi:10.1001/jamaoncol.2016.6615

Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer

Abstract Full Text
JAMA Oncol. 2018;4(2):263-264. doi:10.1001/jamaoncol.2016.7019

Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer

Abstract Full Text
JAMA Oncol. 2018;4(2):264. doi:10.1001/jamaoncol.2017.3407

Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer—Reply

Abstract Full Text
JAMA Oncol. 2018;4(2):265. doi:10.1001/jamaoncol.2017.3410
Correction

Error in Title of Letter to the Editor

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):265. doi:10.1001/jamaoncol.2017.4247
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):149. doi:10.1001/jamaoncol.2017.3204
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2018;4(2):143. doi:10.1001/jamaoncol.2017.3203
×